title: Suppression of ovarian activity with a low-dose 21/7-day regimen oral contraceptive containing ethinylestradiol 20 mcg/drospirenone 3 mg in Japanese and Caucasian women.
abstract: BACKGROUND
  Two studies assessed the effect of a low-estrogen-dose 21/7-day oral contraceptive containing ethinylestradiol and drospirenone (EE 20 mcg/drsp 3 mg) on ovarian activity in Japanese and Caucasian women.
  
  
  METHODS
  Study 1 was conducted in Japanese women (20-35 years), and Study 2 was conducted in Caucasian women (18-35 years). All women received EE 20 mcg/drsp 3 mg in a 21-day active pill regimen. The primary endpoint was the proportion of women with ovulation inhibition (Hoogland score <6; as assessed by transvaginal ultrasonography) during treatment cycle 2.
  
  
  RESULTS
  Japanese (n=23) and Caucasian (n=30) women received two cycles of study treatment. During treatment cycle 2, ovulation was inhibited in 100% and 92.9% of Japanese and Caucasian women, respectively.
  
  
  CONCLUSIONS
  EE 20 mcg/drsp 3 mg in a 21/7-day regimen provides comparable ovarian suppression in Japanese and Caucasian women, with normal ovarian function resuming shortly after treatment end in both populations.
authors.affiliation: Department of Obstetrics and Gynecology, NYU-Langone Medical Center, New York 10017, USA. yuzuru.anzai@nyumc.org
authors.forename: Yuzuru
authors.initials: Y
authors.lastname: Anzai
authors.forename: Doris
authors.initials: D
authors.lastname: Heger-Mahn
authors.forename: Ilka
authors.initials: I
authors.lastname: Schellschmidt
authors.forename: Joachim
authors.initials: J
authors.lastname: Marr
mesh_terms: D000293:Adolescent; D000328:Adult; D000736:Androstenes / Q000008:administration & dosage* / Q000009:adverse effects; D044466:Asian People; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects; D004967:Estrogens / Q000008:administration & dosage* / Q000009:adverse effects; D004997:Ethinyl Estradiol / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007564:Japan; D000451:Mineralocorticoid Receptor Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D010053:Ovary / Q000187:drug effects*; D010060:Ovulation / Q000187:drug effects; D010349:Patient Compliance; D011247:Pregnancy; D044465:White People; D055815:Young Adult
chemical_list: D000736:Androstenes; D003277:Contraceptives, Oral, Combined; D004967:Estrogens; D000451:Mineralocorticoid Receptor Antagonists; D004997:Ethinyl Estradiol; C035144:drospirenone